Abstract. Using autologous ""1I-fibrinogen, we made studies of the metabolism and distribution of fibrinogen in 10 patients with hemophilia A. In two patients simultaneous studies of autologous 13I-fibrinogen and homologous 125I-fibrinogen prepared from healthy donors' plasma were carried out. The average value for the plasma volume was 42.1 ± 8.8 ml/kg; for the plasma fibrinogen concentration, 349 + 90 mg/100 ml; for the intravascular fibrinogen, 144 ± 32 mg/kg; for the interstitial fibrinogen, 30 ± 11 mg/kg; for the slower half-life of 11I-fibrinogen, 2.34 + 0.17 days; for the transcapillary transfer rate of fibrinogen, 109 + 37 mg/kg per day; and for the catabolic and synthetic rates of fibrinogen, 51.7 + 13.1 mg/kg per day. Comparison of these results with those of the previous study in healthy male subjects showed that in patients with hemophilia A the catabolic and synthetic rates of fibrinogen are markedly increased, whereas the plasma fibrinogen concentration, intravascular and interstitial fibrinogen, and the transcapillary transfer rate of fibrinogen are not significantly different. The simultaneous studies of autologous 131I-fibrinogen and normal homologous 125I-fibrinogen in two subjects revealed that the two preparations behaved very similarly. Based on these findings, we concluded that our present findings are not due to the qualitative difference between the hemophilia A and normal fibrinogens, but that they are due to the difference in the host condition with respect to the fibrinogen metabolism, which is either an increased rate of direct breakdown of fibrinogen or an increased rate of fibrinogen breakdown after fibrin formation, or both.
Introduction
It has been reported that fibrinolytic activity in patients with hemophilia A is increased (1, 2) and that e-aminocaproic acid is effective in reducing the incidence of hemorrhage (2) and also hemostasis after dental extraction in such patients (3) . However, other reports claim that c-aminocaproic acid is not effective in reducing the incidence or severity of hemorrhage (4) . Therefore, it seemed--*Received for publication 5 May 1967 and in revised form 8 July 1967.
This work was jointly supported by research grant HE-02262 from the National Heart Institute and research grant FR-00051-05 from the U. S. Public Health Service. of interest to see whether there is any alteration of fibrinogen metabolism in patients with hemophilia A. We therefore studied the metabolism and distribution of fibrinogen in 10 male patients with hemophilia A, using autologous 131I-fibrinogen in eight patients and autologous 131I-fibrinogen and homologous 125I-fibrinogen simultaneously in two patients. Methods
The subjects were male patients with hemophilia A who have been under study at Colorado General Hospital for many years. They ranged in age from. 10 to 54 yr, and all had a family history of hemophilia A. The general experimental procedure was the same as described previously (5) . The preparation of "I-or 'I-fibrinogen was carried out by the previous methods (5) . The clottability of prepared fibrinogen and labeled fibrinogen (6) averaged 96%. At the start of the experiment, 20 --30 uc of 'I-fibrinogen prepared from the subjects' own 1979 plasma was injected intravenously into the subjects, and in two subjects homologous "I-fibrinogen prepared from the plasma of healthy donors was injected simultaneously.
The injected "'lI-or l"I-fibrinogen contained about 5 mg fibrinogen. The first blood sample was obtained at 15 min postinjection and subsequent samples were obtained 0.125, 0.25, 1, 2, 3, 4, 5, 6, 7, and sometimes 8 days postinjection. The samples were heparinized. 24-hr urine collections were made daily. The samples were assayed for radioactivity in a well scintillation counter (NuclearChicago Corp., Des Plaines, Ill., model 8725) with spectrometer and a sensitivity of approximately 8 X 10 cpm/,/c of "~'I above the background of 20 cpm and about the same sensitivity for 'I above the background of 15 cpm. The total radioactivity remaining in the body at any time after initial injection of 31..I-or 'I-fibrinogen was measured daily as described elsewhere (5), and in some cases it was doubly checked by whole body counting. The whole body counter was equipped with a 4 X 9 inch NaI crystal and 512 Channel analyzer (model 120, Nuclear Data Corp.). The counting was done by the State of Colorado Department of Public Health. The plasma volume (5) and the plasma fibrinogen concentration were measured as described previously (6) . The microhematocrit and the erythrocyte sedimenattion rate [Wintrobe's method (7)] were measured on all blood samples. Some plasma samples were analyzed for radioactivity unbound to fibrinogen (5) and euglobulin fibrinolysis time (8) . In all subjects studied the euglobulin fibrinolysis time was within the normal limit, 2-6 hr. The recalcification time (9), serum prothrombin time, (9) and Lee-White clotting time (9) were also determined by Dr. K. N. von Kaulla and his staff, and in all subjects they were found to be abnormal. The diagnosis of hemophilia A was made by noncorrection of the shorter serum prothrombin time upon addition of normal serum and by its correction upon addition of BaSOc-treated normal plasma. The tracer data were analyzed by the previous methods (10) (11) (12) (13) . (10) , and j3.
Results
= [u2,,/t2,W(t3 -t2)] X (6 -a)/k5] (10), whereiu2,3 is the total radioactivity excreted in the urine during the time interval t2 to t,, t2,3 is the mean plasma fibrinogen radioactivity during the same interval, and ks is the daily fractional excretion rate of the breakdown products or i3ll-or "'I.fibrinogen per day (13) . s2 is the "variance of the fit" (14) . In subjects M.C. and P.C. the data on both autologous (a) 'I-fibrinogen and normal homologous (h) 2'I-fibrinogen are given. SD are given where ± signs appear.
sample, and these data were analyzed by the method of least squares (14) (Table II) (14) . One of the typical experiments is shown in Fig. 1 (5, 13). In Fig. 1 a typical z curve shows that after a day or two z is closely described by a function in the form of z = Czeazt. It is also seen in Fig. 2 Thus, the general behavior of z is similar to that in healthy subjects (5), but its rate of decline appears more rapid than that in healthy subjects (5). represent the radioactivities of the plasma 'I-fibrinogen, the breakdown products of "I-fibrinogen in the iodide space, and the total radioactivity remaining in the body at time t, respectively, and are expressed as fractions of the total radioactivity initially injected. C1 is the intercept of the slower component of x with the ordinate at zero time, and Cs is the intercept of the 1 -u curve with the ordinate at zero time. isj is the fraction of plasma fibrinogen catabolized per day and is calculated from x and u, the cumulative radioactivity excreted in the urine up to time t (10) . The 'I-fibrinogen was prepared from the subject's own plasma.
plotted against time, after a day or two in all experiments, 1 -u is described by the exponential equation 1 -u = C3e-aut. The values of C3 and au were determined by the method of least squares by the IBM 7044 digital computer (14) . The average values of C3 and au, with their SD were 1.19 ± 1 SD of 0.01 and 0.288 ± 1 SD of 0.002/day, respectively, and the "variance of the fit" averaged 6 x 10-5 (14). In Fig. 2 it is shown that the 1 -u curve of autologous 13lI-fibrinogen and that of normal homologous 125I-fibrinogen were very similar. One of the typical whole body radioactivity curves is shown in Fig. 1 , which is in close *jaw is the amount of intravascular fibrinogen filtered through the capillaries per day. j3pt is the amount of intravascular fibrinogen catabolized per day. y is the interstitial fibrinogen. ,/1 is the ratio of the interstitial to the intravascular fibrinogen. F(T) is the function describing the passage time distribution of interstitial fibrinogen. In subjects M. C. and P. C. the results obtained by both autologous (a) '311-fibrinogen and normal homologous (h) "51-fibrinogen are given.
However, the radioactivity caused by 131I or 125I in the plasma never exceeded 3%o of the total plasma fibrinogen radioactivity.
Fractional rates, ij and j1 (j3h and j3u), and their fluxes, jlf and j3X. Table II gives the data on the fraction of plasma fibrinogen filtered through the capillaries per day (]j) and the fraction of plasma fibrinogen catabolized per day j3(UO and j3U). Analyses showed that ji is not significantly different (0.1 > P > 0.05) whereas 13 is markedly increased (0.001 > P), compared with the values in healthy subjects (5) . The values of j3p are in close agreement with hu (Table   II) . The daily values of j3u are shown in Fig. 1 , which stayed nearly constant during the study except for the first 2 days. Table III gives the data on the amount of fibrinogen filtered through the capillaries per day (jlp) and the amount of fibrinogen catabolized per day (h3i). Analysis showed that j1I is not significantly different (0.3 > P > 0.2), but jJ is markedly increased (0.001 > P) compared with the values in healthy subjects (5) . The catabolic rate (jr?) equals thesynthetic rate since the subjects were in or near steady state. Therefore, the latter was also increased.
Interstitial fibrinogen (9) and its passage time distribution through the interstitial fluids [F (T)]. Table III gives the data on y, y/IX, and F(T), which were obtained by previous methods (11, 12) . Analyses showed that 9 (0.2 > P > 0.1), y/IX (0.3 > P > 0.1), and F1 (T) (0.2 > P > 0. 1) are not significantly different compared with the values in healthy subjects (5) .
Discussion A few studies of 131I-fibrinogen metabolism in patients with hemophilia A have been reported previously (15) (16) (17) . Thus, Rausen, Cruchaud, McMillan, and Gitlin (15) studied six cases of patients with hemophilia A and reported an average half-life of 3.0 days. By comparing these results with those of other investigators who found a range of 1.5-6.0 days in healthy subjects, Rausen and co-workers concluded that the half-life of fibrinogen in patients with hemophilia A is not prolonged. Hart (16) published a study of fibrinogen metabolism in one case of hemophilia A and concluded that the half-life of fibrinogen in patients with hemophilia A is similar to that in healthy subjects. Blomback, Carlson, Franzen, and Zetterqvist (17) also did not find significant difference in half-life value between normal and hemophilia A subjects in their studies of two hemophilia A patients. Half-lives alone are insufficient to define fibrinogen metabolism.
The present study shows that in patients with hemophilia A in Denver, plasma fibrinogen concentration and plasma fibrinogen (x) were not significantly different compared with the values in healthy subjects (5) . However, the half-life of plasma 131I-fibrinogen was significantly shorter, and as a result, the fraction of plasma fibrinogen catabolized per day j3 (j3p, 13u) was significantly increased over the value in healthy subjects (5), whereas the fraction of plasma fibrinogen filtered through the capillaries per day (jl) was unchanged; because of the increase in j3 the catabolic flux (j3X) was markedly increased (Table III) . In the steady state j3X equals the synthetic rate of fibrinogen. Since the subjects were in or near steady state, the latter was also increased. However, the transcapillary flux of fibrinogen (jp1) and the interstitial fibrinogen (y) were not significantlv different (Table III) . Question may be raised whether the observed shorter half-life of autologous 131I-fibrinogen and the increased j3 and j3X (Tables II and III) in patients with hemophilia A might have been due to the difference in the amount of contaminant proteins such as antihemophilic globulin within the labeled preparations. As stated earlier and in the previous report (5) the clottability of the present 131I-fibrinogen prepared from each patient's own plasma and the previous 125I-fibrinogen prepared from each healthy subject's own plasma (5) was 96%. Therefore, the maximum amount of contaminant protein was 4%o. Hemophilia A plasma lacks or is deficient in antihemophilic globulin. Therefore, the amount of contaminant antihemophilic globulin within the present 'I-fibrinogen should be less than that in the previous 125I-fibrinogen, since exactly the same method of preparation was used (5) . Antihemophilic globulin has been reported to have a half-life of several hours (21, 22) . Therefore, a longer half-life should be expected for the present 131I-fibrinogen compared with that of the previous 125I-fibrinogen (5) , if the contaminant antihemophilic globulin played a significant part, and the observed shorter half-life of 13'I-fibrinogen in hemophilia A patients cannot be explained on this basis. The next question is whether or not there is any physicochemical difference between hemophilia A and normal fibrinogens and if this is responsible for the observed findings (Tables I,  II, and III) . In an attempt to answer this question at least partially, autologous 131I-fibrinogen prepared from the subject's own plasma and normal homologous 125I-fibrinogen prepared from the plasma of healthy donors were simultaneously studied and their behavior was compared in two hemophilia A patients (Tables I, II, and III). As shown in Fig. 2 , their in vivo behavior was closely similar and, as a result, the plasma volume, plasma fibrinogen concentration, x, jil jar, j3, j3X, S!, and F (T) obtained simultaneously by the two preparations were also closely similar. These results prove that the hemophilia and normal fibrinogens are at least metabolically similar and support the earlier report (23) that hemophilia A fibrinogen is not qualitatively different from normal fibrinogen. Another possible criticism is that the observed shorter half-life of autologous 131I-fibrinogen might have been due to a hemorrhage during the study. If it is assumed that the increase in j3 (Table II) was due entirely to a hemorrhage. then, the subjects must lose about 11% of the total plasma fibrinogen daily (0.358 -0.246 = 0.112 day-) (Table II) (5) , which amounts to about 300 ml plasma daily and should have been large enough to be detected clinically. Furthermore, the relative constancy of hematocrit and plasma fibrinogen concentration during the study speaks against the idea that the observed findings were due to hemorrhagic episodes. Further question may be raised; are the observed difference in fibrinogen metabolism due to the age difference between the normal and hemophilia A subjects or are they due to the seasonal variation in fibrinogen metabolism? Examination of the previous (5) and present data shows that there is no noticeable correlation between plasma fibrinogen concentration or half-life of 131I-fibrinogen and the subject age. The control and present studies were carried out in about the same seasons of the year, and a few studies of healthy subjects during or upon completion of the hemophilia study gave values of fibrinogen metabolism close to the previous results (5) . Thus, the only alternative explanation is the abnormal host condition with respect to the fibrinogen metabolism, which is either an increased rate of direct breakdown of fibrinogen or an increased rate of fibrinogen breakdown after fibrin formation, or both (5) , although the present study is unable to determine which. Nevertheless, the finding of a faster catabolism of fibrinogen in hemophilia A patients with defective clotting mechanisms suggests an increased rate of direct breakdown of fibrinogen with insignificant fibrin formation.
